Vertex Pharma.

Cambridge biotech company Vertex Pharmaceuticals Inc. paid its departing chief executive, Matthew W. Emmens, $13.3 million last year, down from $14.9 million in 2010, according to a regulatory filing. His compensation included a $1.1 million salary, an incentive plan payment of $3 million, and stock and option grants totaling $9.1 million. He stepped down Feb. 1. Jeffrey Leiden took over the job.